Key result
HGyp at 200 mg/kg significantly reduced body weight (27.62 g vs 35.2 g, p<0.01) and improved blood lipid and glucose levels in mice with high-fat diet-induced glucose metabolic disorders.
Why the study?
Gynostemma pentaphyllum is commonly used for diabetes, but research on its main active constituents and glucose metabolic disorders had not been reported.
Does heat-processed Gynostemma pentaphyllum improve glucose and lipid metabolism in high-fat diet-induced glucose metabolic disorder mice?
Does heat-processed Gynostemma pentaphyllum improve glucose and lipid metabolism in high-fat diet-induced glucose metabolic disorder mice?
Absolute Event Rate: 27.62% vs 35.2%
p-value: p=<0.01
Heat-processed Gynostemma pentaphyllum alleviates high-fat diet-induced glucose metabolic disorders in mice by improving lipid and glucose metabolism, potentially via the AGE-RAGE signaling pathway.
Supports further HGyp investigation in metabolic disorders; hypothesis-generating in mice only and should not change practice.
Glucose metabolic disorders (GMD) can promote insulin resistance (IR) and diabetes, and damage liver and kidney. Gynostemma pentaphyllum is commonly used in the clinical treatment of diabetes, but the research on its main active constituents and GMD has not been reported yet. This study explores the therapeutic potential of gypenosides of heat-processed Gynostemma pentaphyllum (HGyp) on high-fat diet-induced GMD in mice. HGyp was administered at different doses for 12 weeks. The investigation encompassed an array of parameters, including body weight, blood lipids, blood glucose, and liver tissue components. Metabolomic and network analyses were conducted to uncover potential targets and pathways associated with HGyp treatment. The results revealed that HGyp alleviated GMD by reducing body weight, blood glucose, and improving blood lipids levels, while increasing liver glycogen and antioxidant enzyme levels. Additionally, HGyp exhibited protective effects on liver and kidney health by reducing tissue damage. Fourteen blood components were detected by LC-MS. Metabolomic and network analyses indicated the potential engagement of the AGE-RAGE signaling pathway in the therapeutic effects of HGyp.Furthermore, Western blot and ELISA assays confirmed that HGyp upregulated GLO1 and GLUT4 while down-regulating AGEs and RAGE expression in liver tissue. In light of these findings, HGyp demonstrates promise as a potential therapeutic candidate for combating GMD, warranting further exploration in the development of therapeutic strategies or functional products.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2023) studied High fat diet-induced glucose metabolic disorders (n=60). Gypenosides of heat-processed Gynostemma pentaphyllum (HGyp) vs. High-fat diet (HFD) control was evaluated on Body weight at 12 weeks (p=<0.01). HGyp at 200 mg/kg significantly reduced body weight (27.62 g vs 35.2 g, p<0.01) and improved blood lipid and glucose levels in mice with high-fat diet-induced glucose metabolic disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: